sandocal effervescent 1000 milligram tablets
glaxosmithkline consumer healthcare (ireland) limited - calcium lactogluconate, calcium carbonate - tablets - 1000 milligram - calcium
caltrate 500 mg / 1000 iu, chewable tablets
glaxosmithkline consumer healthcare (ireland) limited - cholecalciferol concentrate ; calcium carbonate - chewable tablet - 500 mg/1000 international unit(s) - calcium, combinations with vitamin d and/or other drugs
advil cold & flu coated tablets ibuprofen 200 mg pseudoephedrine hydrochloride 30 mg
glaxosmithkline consumer healthcare (ireland) limited 12, riverwalk, citywest business campus, dublin 24, ireland - ibuprofen, pseudoephedrine hydrochloride - coated tablet - ibuprofen 200 mg pseudoephedrine hydrochloride 30 mg - antiinflammatory and antirheumatic products
augmentin 875/125 milligram film coated tablet
glaxosmithkline consumer healthcare (ireland) limited - amoxicillin trihydrate clavulanate potassium - film coated tablet - 875/125 milligram
niquitin minis cherry flavour 4 milligram lozenges
glaxosmithkline consumer healthcare (ireland) limited - nicotine resinate - lozenges - 4 milligram
niquitin minis cherry flavour 1.5 milligram lozenges
glaxosmithkline consumer healthcare (ireland) limited - nicotine resinate - lozenges - 1.5 milligram
zoviduo 50mg/g and 10mg/g cream
glaxosmithkline consumer health-care uk trading limited - aciclovir; hydrocortisone - cream - aciclovir 50 mg; hydrocortisone 10 mg - antibiotics and chemotherapeutics for dermatological use
flixonase allergy 50mcg/actuation nasal spray, suspension
glaxosmithkline consumer health-care uk trading limited - fluticasone propionate - nasal spray, suspension - fluticasone propionate 0.5 mg - nasal preparations
prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals
glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.
adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)
glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.